title: [Pharmacokinetics of 99mTc-MAG3 and 131I-OIH: comparative study based on 2 compartment model analysis].
abstract: We studied 50 patients with mild to moderate renal dysfunction to compare pharmacokinetics of 99mTc-MAG3 with that of 131I-OIH. After simultaneous bolus injection of both 99mTc-MAG3 and 131I-OIH, 8-point venous blood sampling was performed from 2 to 44 min post injection. Aliquoted plasma samples were counted for radioactivity along with the injected standard to obtain % injected dose/ml plasma for each tracer. Using obtained time-concentration data, classical 2 compartment model analysis was performed for both tracers to obtain various pharmacokinetic parameters, including distribution volumes (Vds), inter-compartmental rate constants, and plasma clearance. In these parameters, Vd of central compartment, Vd at steady state, central to peripheral inter-compartmental rate constant, and plasma clearance were significantly larger for 131I-OIH. In all parameters, significant correlation was found between 99mTc-MAG3 and 131I-OIH. The best correlation was seen in plasma clearance (r = 0.891, p < 0.0001). Plasma clearance ratio (99mTc-MAG3/131I-OIH), however, showed weak but significant negative correlation with serum creatinine, although this correlation was not likely to affect the overall correlation of clearance between 131I-OIH and 99mTc-MAG3. From these results, we confirmed that 99mTc-MAG3 clearance could be used as an alternative to 131I-OIH clearance, although pharmacokinetic behavior of 99mTc-MAG3 was not exactly the same as that of 131I-OIH.
authors.affiliation: Department of Radiology, Asahikawa Medical College Hospital.
authors.forename: N
authors.initials: N
authors.lastname: Shuke
authors.forename: T
authors.initials: T
authors.lastname: Takashio
authors.forename: J
authors.initials: J
authors.lastname: Sato
authors.forename: Y
authors.initials: Y
authors.lastname: Ishikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Saito
authors.forename: W
authors.initials: W
authors.lastname: Yamamoto
authors.forename: T
authors.initials: T
authors.lastname: Aburano
authors.forename: M
authors.initials: M
authors.lastname: Mizunaga
authors.forename: S
authors.initials: S
authors.lastname: Kaneko
authors.forename: S
authors.initials: S
authors.lastname: Yachiku
authors.forename: Y
authors.initials: Y
authors.lastname: Ogawa
authors.forename: K
authors.initials: K
authors.lastname: Kikuchi
authors.forename: T
authors.initials: T
authors.lastname: Sasajima
authors.forename: Y
authors.initials: Y
authors.lastname: Kubo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D006801:Humans; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D007465:Iodohippuric Acid / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D013667:Technetium / Q000493:pharmacokinetics*
chemical_list: D007457:Iodine Radioisotopes; D007465:Iodohippuric Acid; C096273:N-(mercaptoacetyl)glycine; D013667:Technetium; D005998:Glycine